Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
This study was undertaken to investigate safety and scar-improvement activity of different
applications of Juvista (avotermin), administered to surgical incisions made to the skin of a
healthy population of male volunteers aged 18-45 years. The study addressed two issues:
whether Juvista (avotermin) administered at 200ng/100μl/linear cm wound margin is more
effective than 50ng/100μl/linear cm for scar improvement and, secondly, whether dosing once
only (before wounding) or twice (before and after wounding) is optimal for scar improvement.